Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated January 23, 2026, titled Sun Pharma receives DCGI approval to manufacture and market generic semaglutide injection in India for chronic weight management, .
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sun Pharma has received approval from India's drug regulator (DCGI) to manufacture and market a generic version of semaglutide injection in India, specifically indicated for chronic weight management. Semaglutide is the active ingredient in popular GLP-1 drugs like Ozempic and Wegovy, which have seen massive global demand for obesity treatment. This positions Sun Pharma to enter India's growing weight management drug market with a more affordable generic alternative. The approval gives Sun Pharma a first-mover advantage in the Indian generic semaglutide space for weight management.
This is a positive development for Sun Pharma as it opens a new, high-growth therapeutic segment. Chronic weight management is a rapidly expanding market both globally and in India, and early generic entry could drive meaningful incremental revenue, though near-term financial impact will depend on pricing, launch scale, and competition from innovator brands.